(+)-DDMS (R-Didesmethylsibutramine , (R)-DDMS) is one of sibutramine active metabolites. Sibutramine is widely used in the treatment of obesity. Sibutramine acts by inhibiting the reuptake of serotonin and noradrenaline in synapses, thereby enhancing both satiety and energy expenditure. In preclinical models (R)-enantiomer of Didesmethylsibutramine was clearly more potent than the (S)-enantiomers and (R)-didesmethylsibutramine shows some activity in all tests. (S)-didesmethylsibutramine affected locomotor behavior and the Porsolt test but appeared to be completely inactive on food intake. R-Didesmethylsibutramine is more potent than sibutramine in depressing food intake and decreasing body weight, suggest that these enantioselective metabolites might be safer and more effective than sibutramine as potential therapies for obesity.

Glyceryl 2-linoleate is a fatty acid derivative. It inhibits monoacylglycerol lipase and fatty acid amide hydrolase activity. Glyceryl 2-linoleate enhanced a 2-Arachidonoyl-glycerol inhibition of tumor necrosis factor alpha production in murine macrophages when applied with 2-Arachidonoyl-glycerol. Initially, it was found that Glyceryl 2-linoleate potentiated the apparent binding of 2-Arachidonoyl-glycerol to cannabinoid receptors CB1 and CB2. However, later research revealed that in no case do the lipid Glyceryl 2-linoleate acts as entourage compounds for 2-Arachidonoyl-glycerol. Increase in Glyceryl 2-linoleate plasma concentrations was observed in cocaine subjects diagnosed with psychiatric comorbidity.